The discovery of RNA interference caused a revival of the concept of short nucleic acids application as molecular tools for therapeutic control of gene expression. After almost a decade of intensive research by leading pharmaceutical companies, there is only a limited number of clinical trials of synthetic siRNAs. In this review, we shall summarize the present status of knowledge of RNAi mechanism of action and discuss the potential of the use of siRNA in theraphy. We shall also provide data on recent achievements in current clinical trials based on RNAi techniques.
Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.
Oct 2, 2020
Jun 15, 2019
|RNAi w terapii||Oct 2, 2020|
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Nowak, Jacek K.
Sierant, Małgorzata Nawrot, Barbara
Antoszczyk, Sławomir Nawrot, Barbara